Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (182) 182
oncology (152) 152
index medicus (144) 144
gw572016 (138) 138
female (129) 129
lapatinib (116) 116
trastuzumab (101) 101
breast cancer (93) 93
breast neoplasms - drug therapy (90) 90
lapatinib gw572016 (88) 88
tyrosine kinase inhibitor (69) 69
receptor, erbb-2 - metabolism (64) 64
cancer (61) 61
receptor, erbb-2 - antagonists & inhibitors (60) 60
growth-factor receptor (54) 54
quinazolines - therapeutic use (54) 54
quinazolines - administration & dosage (53) 53
antineoplastic agents - therapeutic use (52) 52
breast neoplasms - metabolism (52) 52
breast neoplasms - pathology (51) 51
cell line, tumor (51) 51
quinazolines - pharmacology (49) 49
antineoplastic combined chemotherapy protocols - therapeutic use (46) 46
her2 (45) 45
middle aged (44) 44
animals (42) 42
expression (41) 41
pharmacology & pharmacy (41) 41
antibodies, monoclonal, humanized (40) 40
adult (38) 38
antineoplastic agents - pharmacology (38) 38
inhibitor (37) 37
chemotherapy (36) 36
receptor, epidermal growth factor - antagonists & inhibitors (36) 36
adjuvant chemotherapy (35) 35
egfr (35) 35
aged (34) 34
antineoplastic agents (33) 33
care and treatment (33) 33
growth (33) 33
quinazolines - adverse effects (33) 33
skin and connective tissue diseases (32) 32
breast-cancer (31) 31
epidermal growth factor (31) 31
therapy (29) 29
treatment outcome (29) 29
antimitotic agents (28) 28
antitumor-activity (28) 28
phase-ii (28) 28
protein kinase inhibitors - therapeutic use (28) 28
analysis (27) 27
capecitabine (27) 27
cell proliferation - drug effects (27) 27
drug resistance, neoplasm (26) 26
monoclonal-antibody (26) 26
quinazolines - pharmacokinetics (26) 26
erbb2 (25) 25
male (25) 25
mice (25) 25
research (25) 25
tyrosine (25) 25
antibodies, monoclonal - therapeutic use (24) 24
tumors (24) 24
cells (23) 23
drug therapy (23) 23
kinases (23) 23
metastasis (23) 23
signal transduction - drug effects (23) 23
apoptosis (22) 22
protein kinase inhibitors - pharmacology (22) 22
receptor, epidermal growth factor - metabolism (22) 22
breast neoplasms - genetics (21) 21
combination (21) 21
dose-response relationship, drug (21) 21
medicine & public health (21) 21
receptor (21) 21
survival (21) 21
antineoplastic agents - administration & dosage (20) 20
clinical trials as topic (20) 20
neoplasms - drug therapy (20) 20
phase-i (20) 20
receptor, erbb-2 - genetics (20) 20
signal transduction (20) 20
hematology, oncology and palliative medicine (19) 19
antibodies, monoclonal - pharmacology (18) 18
metastatic breast-cancer (18) 18
phase-ii trial (18) 18
phosphorylation (18) 18
protein kinase inhibitors - administration & dosage (18) 18
tyrosine kinases (18) 18
cancer therapies (17) 17
trastuzumab resistance (17) 17
activation (16) 16
antineoplastic agents - adverse effects (16) 16
antineoplastic agents - pharmacokinetics (16) 16
antineoplastic combined chemotherapy protocols - pharmacology (16) 16
article (16) 16
brain metastases (16) 16
drug administration schedule (16) 16
in-vitro (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Phase III, Randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: ALTERNATIVE
by Johnston, Stephen R.D and Hegg, Roberto and Im, Seock-Ah and Park, In Hae and Burdaeva, Olga and Kurteva, Galina and Press, Michael F and Tjulandin, Sergei and Iwata, Hiroji and Simon, Sergio D and Kenny, Sarah and Sarp, Severine and Izquierdo, Miguel A and Williams, Lisa S and Gradishar, William J
Journal of Clinical Oncology, ISSN 0732-183X, 03/2018, Volume 36, Issue 8, pp. 741 - 748
PurposeHuman epidermal growth factor receptor 2 (HER2) targeting plus endocrine therapy (ET) improved clinical benefit in HER2-positive, hormone receptor... 
TRIAL | 1ST-LINE TREATMENT | MULTICENTER | ONCOGENE | EFFICACY | ONCOLOGY | GW572016 | OPEN-LABEL | KINASE INHIBITOR | PERTUZUMAB | DOCETAXEL
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Emerging Targeted Therapies for Breast Cancerd
by Alvarez, RH and Valero, V and Hortobagyi, GN
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 07/2010, Volume 28, Issue 20, pp. 3366 - 3379
Increased understanding of the molecular events involved in cancer development has led to the identification of a large number of novel targets and, in... 
GROWTH-FACTOR RECEPTOR | 1ST-LINE TREATMENT | PHASE-II TRIAL | TRANSFERASE INHIBITOR | ONCOLOGY | TYROSINE KINASE INHIBITOR | MONOCLONAL-ANTIBODY | ANTITUMOR-ACTIVITY | LAPATINIB GW572016 | TUMOR-GROWTH | MTOR INHIBITOR
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial
by Di Cosimo, S and Appierto, V and Pizzamiglio, S and Tiberio, P and Iorio, MV and Hilbers, F and de Azambujas, E and de la Pena, L and Izquierdo, M and Huober, J and Baselga, J and Piccart, M and de Braud, FG and Apolone, G and Verderio, P and Daidone, MG
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 07/2019, Volume 25, Issue 13, pp. 3887 - 3895
Purpose: To investigate the potential of circulating-miRNAs (ct-miRNA) as noninvasive biomarkers to predict the efficacy of single/dual HER2-targeted therapy... 
SURVIVAL | PREOPERATIVE CHEMOTHERAPY | ONCOLOGY | GROWTH | DOWN-REGULATION | SECONDARY ANALYSIS | RECEPTOR | OPEN-LABEL | LAPATINIB GW572016 | PLUS TRASTUZUMAB | MICRORNA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
by Baselga, José, Dr and Bradbury, Ian, PhD and Eidtmann, Holger, MD and Di Cosimo, Serena, MD and de Azambuja, Evandro, MD and Aura, Claudia, MD and Gómez, Henry, MD and Dinh, Phuong, MD and Fauria, Karine, PhD and Van Dooren, Veerle, MSc and Aktan, Gursel, MD and Goldhirsch, Aron, MD and Chang, Tsai-Wang, MD and Horváth, Zsolt, MD and Coccia-Portugal, Maria, MD and Domont, Julien, MD and Tseng, Ling-Min, MD and Kunz, Georg, MD and Sohn, Joo Hyuk, MD and Semiglazov, Vladimir, MD and Lerzo, Guillermo, MD and Palacova, Marketa, MD and Probachai, Volodymyr, MD and Pusztai, Lajos, DPhil and Untch, Michael, PhD and Gelber, Richard D, PhD and Piccart-Gebhart, Martine, PhD and NeoALTTO Study Team and Sahlgrenska akademin and Göteborgs universitet and Gothenburg University and Institute of Clinical Sciences, Section for Surgery and Gastrosurgical Research and Education, Department of Surgery and Institutionen för kliniska vetenskaper, sektionen för kirurgi och kirurgisk gastroforskning, Avdelningen för kirurgi and Sahlgrenska Academy
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9816, pp. 633 - 640
Summary Background The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and... 
Internal Medicine | ADJUVANT CHEMOTHERAPY | APOPTOSIS | CELLS | WOMEN | MEDICINE, GENERAL & INTERNAL | GW572016 | ERBB2 | INHIBITOR | PLUS | Breast Neoplasms - surgery | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Diarrhea - chemically induced | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Liver - drug effects | Adult | Female | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Paclitaxel - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Liver - metabolism | Paclitaxel - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Quinazolines - adverse effects | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Drug therapy | Breast cancer | Genetic aspects | Medical research | Ligands | Cytotoxicity | Mammography | Kinases | Cancer therapies | pathology | Liver | methods | Antibodies | Oral | Quinazolines | Breast Neoplasms | Tumor Markers | administration & dosage | Surgery | Paclitaxel | Neoadjuvant Therapy | Adjuvant | Monoclonal | chemistry | Administration | drug therapy | chemically induced | Intravenous | Infusions | Humanized | Antineoplastic Combined Chemotherapy Protocols | Diarrhea | drug effects | Biological | analysis | Kirurgi | antagonists & inhibitors | Chemotherapy | Receptor | adverse effects | metabolism | Cancer and Oncology | therapeutic use | Cancer och onkologi | erbB-2
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
by Robidoux, André, Prof and Tang, Gong, PhD and Rastogi, Priya, MD and Geyer, Charles E, Prof and Azar, Catherine A, MD and Atkins, James N, MD and Fehrenbacher, Louis, MD and Bear, Harry D, MD and Baez-Diaz, Louis, MD and Sarwar, Shakir, MD and Margolese, Richard G, MD and Farrar, William B, Prof and Brufsky, Adam M, Prof and Shibata, Henry R, Prof and Bandos, Hanna, PhD and Paik, Soonmyung, Prof and Costantino, Joseph P, Prof and Swain, Sandra M, Prof and Mamounas, Eleftherios P, Prof and Wolmark, Norman, Prof
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 12, pp. 1183 - 1192
Summary Background We studied the effect on tumour response to neoadjuvant therapy of the substitution of lapatinib for trastuzumab in combination with weekly... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | WOMEN | CELLS | SURGICAL ADJUVANT BREAST | PREOPERATIVE CHEMOTHERAPY | ONCOLOGY | GW572016 | CHEMOTHERAPY PLUS TRASTUZUMAB | PERTUZUMAB | INHIBITOR | DOCETAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Puerto Rico | United States | Humans | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Breast Neoplasms - enzymology | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Biomarkers, Tumor - metabolism | Mastectomy | Female | Neoadjuvant Therapy | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Odds Ratio | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Drug Administration Schedule | Logistic Models | Treatment Outcome | Chi-Square Distribution | Breast Neoplasms - drug therapy | Canada | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Quinazolines - adverse effects | Trastuzumab | Health maintenance organizations | Neoadjuvant therapy | Medical colleges | Care and treatment | Cyclophosphamide | Anthracyclines | Adjuvant treatment | Breast cancer | Product development | Public health | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
by Geyer, Charles E and Forster, John and Lindquist, Deborah and Chan, Stephen and Chan, Arlene and Romieu, C. Gilles and Pienkowski, Tadeusz and Jagiello-Gruszfeld, Agnieszka and Crown, John and Kaufman, Bella and Skarlos, Dimosthenis and Campone, Mario and Davidson, Neville and Berger, Mark and Oliva, Cristina and Rubin, Stephen D and Stein, Steven and Cameron, David
The New England Journal of Medicine, ISSN 0028-4793, 12/2006, Volume 355, Issue 26, pp. 2733 - 2743
Trastuzumab, a humanized monoclonal antibody against the extracellular portion of human epidermal growth factor receptor type 2 (HER2), is effective in... 
ADJUVANT CHEMOTHERAPY | SURVIVAL | MEDICINE, GENERAL & INTERNAL | TRASTUZUMAB | EFFICACY | SAFETY | GW572016 | GROWTH | METASTASES | MONOCLONAL-ANTIBODY | KINASE INHIBITOR | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Protein Kinase Inhibitors - adverse effects | Fluorouracil - therapeutic use | Breast Neoplasms - chemistry | Deoxycytidine - therapeutic use | Fluorouracil - adverse effects | Aged, 80 and over | Adult | Deoxycytidine - adverse effects | Female | Receptor, ErbB-2 - antagonists & inhibitors | Heart Diseases - chemically induced | Fluorouracil - analogs & derivatives | Proportional Hazards Models | Breast Neoplasms - drug therapy | Disease Progression | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Quinazolines - adverse effects | Survival Analysis | Breast Neoplasms - mortality | Aged | Receptor, ErbB-2 - analysis | Deoxycytidine - analogs & derivatives | Drug therapy | Breast cancer | Gene amplification | Epidermal growth factor | Kinases | Womens health | Cancer therapies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
by Joan T. Garrett and María Graciela Olivares and Cammie Rinehart and Nara D. Granja-Ingram and Violeta Sánchez and Anindita Chakrabarty and Bhuvanesh Dave and Rebecca S. Cook and William Pao and Eliot McKinely and H. C. Manning and Jenny Chang and Carlos L. Arteaga and Joan S. Brugge
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 3/2011, Volume 108, Issue 12, pp. 5021 - 5026
Sustained and complete inhibition of HER3 and its output to PI3K/Akt are required for the optimal antitumor effect of therapeutic inhibitors of the HER2... 
Up regulation | Phosphorylation | Messenger RNA | RNA | B lymphocytes | Cell lines | Antibodies | Small interfering RNA | Breast cancer | Tumors | BREAST-CANCER | ACTIVATION | ONCOGENE | THERAPY | AMPLIFICATION | TRASTUZUMAB | MULTIDISCIPLINARY SCIENCES | CARCINOMAS | PHOSPHOINOSITIDE 3-KINASE | LAPATINIB GW572016 | EXPRESSION | Gene Expression Regulation, Enzymologic - drug effects | Neoplasm Transplantation | Transcription, Genetic - drug effects | Humans | Receptor, ErbB-2 - metabolism | Receptor, ErbB-3 - antagonists & inhibitors | Transplantation, Heterologous | Phosphatidylinositol 3-Kinases - metabolism | Breast Neoplasms - drug therapy | Receptor, ErbB-3 - biosynthesis | Up-Regulation - drug effects | Breast Neoplasms - enzymology | Animals | Mice, Nude | Female | Mice | Protein Kinase Inhibitors - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Gene Expression Regulation, Neoplastic - drug effects | Proto-Oncogene Proteins c-akt - metabolism | Quinazolines - pharmacology | Post-translational modification | Tyrosine | Genetic aspects | Genetic transcription | Research | Phosphotransferases | Health aspects | Biological Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network
by Christoph A. Ritter and Marianela Perez-Torres and Cammie Rinehart and Marta Guix and Teresa Dugger and Jeffrey A. Engelman and Carlos L. Arteaga
Clinical Cancer Research, ISSN 1078-0432, 08/2007, Volume 13, Issue 16, pp. 4909 - 4919
Purpose: We have investigated mechanisms of acquired resistance to the HER2 antibody trastuzumab in BT-474 human breast cancer cells. Experimental Design:... 
trastuzumab | ErbB2 | EGF receptor | breast cancer | drug resistance | HER2 | neu | ADJUVANT CHEMOTHERAPY | SIGNAL-TRANSDUCTION | FACTOR EGF | ONCOLOGY | DOWN-REGULATION | TYROSINE KINASE INHIBITOR | HERCEPTIN-INDUCED INHIBITION | EXTRACELLULAR DOMAIN | MONOCLONAL-ANTIBODY | LAPATINIB GW572016 | PHASE-I | Signal Transduction | Antibodies, Monoclonal - pharmacology | Drug Resistance, Neoplasm | Receptor, Epidermal Growth Factor - analysis | Breast Neoplasms - drug therapy | Antibodies, Monoclonal, Humanized | Receptor, ErbB-2 - physiology | Animals | Cell Line, Tumor | Female | Ligands | Antineoplastic Agents - pharmacology | Mice | Mice, Inbred BALB C | Receptor, ErbB-2 - analysis | Receptor, Epidermal Growth Factor - physiology | Trastuzumab | Transforming Growth Factor alpha - pharmacology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Estradiol and Tamoxifen Induce Cell Migration through GPR30 and Activation of Focal Adhesion Kinase
by Tsai, CL and Wu, HM and Lin, CY and Lin, YJ and Chao, A and Wang, TH and Hsueh, S and Lai, CH and Wang, HS
PLOS ONE, ISSN 1932-6203, 09/2013, Volume 8, Issue 9
Estrogens and tamoxifen (an antiestrogen) exert their actions by activation of estrogen receptor (ER) through genomic and non-genomic mechanisms and are... 
INDUCED PHOSPHOPROTEIN 1 | BREAST-CANCER | GROWTH-FACTOR RECEPTOR | PROTEIN-COUPLED RECEPTOR | MULTIDISCIPLINARY SCIENCES | GENE-EXPRESSION | 4-HYDROXYTAMOXIFEN | PROLIFERATION | INHIBITOR | LAPATINIB GW572016 | 17-BETA-ESTRADIOL
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Cellular Adaptive Immune System Plays a Crucial Role in Trastuzumab Clinical Efficacy Reply
by Spector, NL and Blackwell, KL
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 07/2010, Volume 28, Issue 21, pp. E371 - E371
BREAST-CANCER | LAPATINIB | CELLS | ONCOLOGY | GW572016 | INHIBITOR
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer
by Burstein, H. J and Storniolo, A. M and Franco, S and Forster, J and Stein, S and Rubin, S and Salazar, V. M and Blackwell, K. L
Annals of Oncology, ISSN 0923-7534, 6/2008, Volume 19, Issue 6, pp. 1068 - 1074
Background: The efficacy and tolerability of the epidermal growth factor receptor/human epidermal growth factor receptor type 2 (HER2) tyrosine kinase... 
Breast cancer | ErbB2 | Targeted therapy | Tyrosine kinase inhibitor | EGFR | Trastuzumab | targeted therapy | CELLS | ACTIVATION | breast cancer | TRASTUZUMAB RESISTANCE | trastuzumab | GROWTH-FACTOR RECEPTOR | IN-VITRO | AMPLIFICATION | THERAPY | ONCOLOGY | GW572016 | tyrosine kinase inhibitor | CONTRIBUTES | Breast Neoplasms - secondary | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Genes, erbB-2 | Quinazolines - therapeutic use | Humans | Middle Aged | Adult | Female | Aged | Antineoplastic Agents - therapeutic use | Breast Neoplasms - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: A randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer - CALGB 40302 (alliance)
by Burstein, Harold J and Cirrincione, Constance T and Barry, William T and Chew, Helen K and Tolaney, Sara M and Lake, Diana E and Ma, Cynthia and Blackwell, Kimberly L and Winer, Eric P and Hudis, Clifford A
Journal of Clinical Oncology, ISSN 0732-183X, 12/2014, Volume 32, Issue 35, pp. 3959 - 3966
Purpose CALGB 40302 sought to determine whether lapatinib would improve progression-free survival (PFS) among women with hormone receptor-positive metastatic... 
PATHWAYS | ONCOLOGY | GW572016 | SAFETY | TAMOXIFEN | RESISTANCE | TYROSINE KINASES | MCF-7 CELLS | REGIMENS | ESTROGEN-RECEPTOR | ANASTROZOLE | Estradiol - analogs & derivatives | Receptors, Estrogen - metabolism | Double-Blind Method | Antineoplastic Agents, Hormonal - administration & dosage | Humans | Middle Aged | Estradiol - administration & dosage | Hormones - therapeutic use | Proportional Hazards Models | Receptor, ErbB-2 - metabolism | Treatment Outcome | Breast Neoplasms - drug therapy | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Postmenopause | Adult | Female | Quinazolines - administration & dosage | Aged | Chemotherapy, Adjuvant | Index Medicus | Bc6 | ORIGINAL REPORTS | Bc7
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancers
by Bhuvanesh Dave and Ilenia Migliaccio and M. Carolina Gutierrez and Meng-Fen Wu and Gary C. Chamness and Helen Wong and Archana Narasanna and Anindita Chakrabarty and Susan G. Hilsenbeck and Jian Huang and Mothaffar Rimawi and Rachel Schiff and Carlos Arteaga and C. Kent Osborne and Jenny C. Chang
Journal of Clinical Oncology, ISSN 0732-183X, 01/2011, Volume 29, Issue 2, pp. 166 - 173
Purpose Phosphatase and tensin homolog (PTEN) loss or activating mutations of phosphoinositol-3 (PI3) kinase (PIK3CA) may be associated with trastuzumab... 
PATHWAYS | CELLS | APOPTOSIS | ONCOLOGY | GW572016 | RESISTANCE | DIFFERENTIATION | INHIBITORS | ANTITUMOR-ACTIVITY | CONTRIBUTES | CHEMOTHERAPY | RNA, Small Interfering - genetics | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Phosphatidylinositol 3-Kinases - metabolism | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Antibodies, Monoclonal, Humanized | Breast Neoplasms - enzymology | Transfection | Adult | Female | Neoadjuvant Therapy | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | PTEN Phosphohydrolase - genetics | Receptor, ErbB-2 - biosynthesis | Antibodies, Monoclonal - pharmacology | PTEN Phosphohydrolase - metabolism | Breast Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Taxoids - administration & dosage | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cell Line, Tumor | Aged | Enzyme Activation | Mutation | Quinazolines - pharmacology | RNA, Small Interfering - administration & dosage | Trastuzumab | Clinical Trials, Phase II as Topic | Original Reports | To14 | To11 | Bc8 | To2
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Pharmacokinetics of Lapatinib, a Nonrenally Cleared Drug, in Patients With End‐Stage Renal Disease on Maintenance Hemodialysis
by Pai, Sudhakar M and Chaikin, Philip and Berg, Jolene Kay
The Journal of Clinical Pharmacology, ISSN 0091-2700, 10/2019, Volume 59, Issue 10, pp. 1379 - 1383
Lapatinib, a tyrosine kinase inhibitor, is approved for the treatment of breast cancer. The literature shows that it is metabolized by CYP3A4 and eliminated... 
ESRD | lapatinib | hemodialysis | pharmacokinetics | renal impairment | KIDNEY-DISEASE | IMPACT | METABOLISM | GW572016 | PHARMACOLOGY & PHARMACY | INHIBITOR | Tyrosine | Renal function | Hemodialysis | Drug interactions | Impairment | Clinical trials | Breast cancer | Pharmacology | Kinases | Drug interaction | Dialysis | Kidney diseases | Pharmacokinetics | Protein-tyrosine kinase | Drug dosages | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: Molecular docking study
by El-Azab, Adel S and Al-Omar, Mohamed A and Abdel-Aziz, Alaa A.-M and Abdel-Aziz, Naglaa I and El-Sayed, Magda A.-A and Aleisa, Abdulaziz M and Sayed-Ahmed, Mohamed M and Abdel-Hamide, Sami G
European Journal of Medicinal Chemistry, ISSN 0223-5234, 2010, Volume 45, Issue 9, pp. 4188 - 4198
Novel derivatives of quinazoline ( – ) have been synthesized and tested for their antitumor activity against three tumor cell lines among these cell lines the... 
Drug-likeness | Synthesis | Quinazoline | Molecular docking | Antitumor | CHEMISTRY, MEDICINAL | SERIES | ANALOGS | TUMOR-CELLS | CANCER | TYROSINE KINASE INHIBITORS | LAPATINIB | GW572016 | GROWTH | CYTOTOXICITY | Quinazolines - chemical synthesis | Antineoplastic Agents - chemical synthesis | Humans | Models, Molecular | Structure-Activity Relationship | Antineoplastic Agents - chemistry | Static Electricity | Receptor, Epidermal Growth Factor - chemistry | Antineoplastic Agents - metabolism | Receptor, Epidermal Growth Factor - metabolism | Hydrogen Bonding | Quinazolines - metabolism | Drug Design | Cell Line, Tumor | Inhibitory Concentration 50 | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Protein Conformation | Antineoplastic Agents - pharmacology | Quinazolines - pharmacology | Quinazolines - chemistry | Antimitotic agents | Epidermal growth factor | Analysis | Pharmacy | Universities and colleges | Antineoplastic agents | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck
by De Souza, Jonas A and Davis, Darren W and Zhang, Yujian and Khattri, Arun and Seiwert, Tanguy Y and Aktolga, Serdal and Wong, Stuart J and Kozloff, Mark F and Nattam, Sreenivasa and Lingen, Mark W and Kunnavakkam, Rangesh and Stenson, Kerstin M and Blair, Elizabeth A and Bozeman, Jeffrey and Dancey, Janet E and Vokes, Everett E and Cohen, Ezra E. W
Clinical Cancer Research, ISSN 1078-0432, 04/2012, Volume 18, Issue 8, pp. 2336 - 2343
Purpose: This study sought to determine the efficacy and safety profile of lapatinib in patients with recurrent/metastatic squamous cell carcinoma of the head... 
SURVIVAL | TRIAL | GROWTH-FACTOR RECEPTOR | CETUXIMAB | ONCOLOGY | RECURRENT | GW572016 | TYROSINE KINASE INHIBITOR | CANCER | EXPRESSION | CHEMOTHERAPY | ErbB Receptors - antagonists & inhibitors | Humans | Head and Neck Neoplasms - drug therapy | Neoplasm Recurrence, Local - drug therapy | Male | Antineoplastic Agents - administration & dosage | Disease-Free Survival | Squamous Cell Carcinoma of Head and Neck | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Agents - adverse effects | Quinazolines - therapeutic use | Quinazolines - adverse effects | Female | Quinazolines - administration & dosage | Lapatinib
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights